For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Kisspeptin-10
Illustration for Kisspeptin-10

THE PEPSRADAR ENCYCLOPEDIA

Kisspeptin-10

Reproductive hormone signaling

Research topics · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Kisspeptin-10 · KEY FACTS

Content updated · how dates work

Saved peptides

What is Kisspeptin-10?

Kisspeptin-10 is a short active kisspeptin sequence studied in reproductive-hormone regulation. Hormonal responses are a starting point for fertility research.

Biological role or research focus

Reproductive hormone signaling.

A short-term hormone response is different from a demonstrated fertility or sexual-function outcome.

Role reference: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. ↗

Names you may encounter

kisspeptin · kisspeptin 10

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Reproductive signaling peptide
Main research area
GnRH and LH physiology
Evidence featured
Small human physiology study
Source check
October 4, 2026

Source: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. ↗

Quick answers

Is Kisspeptin-10 FDA approved?
No. No FDA-approved drug contains Kisspeptin-10. FDA lists it in 503A category 2, substances that may present significant safety risks in compounding. Source ↗
Is Kisspeptin-10 safe?
Kisspeptin-10 is an unapproved reproductive-hormone peptide. Only short studies in small groups of healthy men exist, and FDA lists it as a possible significant safety risk in compounding. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
Is Kisspeptin-10 banned in sport?
Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.1 Testosterone-stimulating peptides in males). Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research
StudyTypePopulation / model
LH secretion experiment (2011)Small human physiology studyHealthy men in small bolus and infusion experiments.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Small human physiology study · 2011

LH secretion experiment

Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.

Population / model
Healthy men in small bolus and infusion experiments.
Study design
Hormone sampling after kisspeptin-10; pulse analysis during infusions.
Main finding
LH increased, and infusion changed LH pulse frequency and size. Testosterone also increased in the prolonged-infusion experiment.
Limits & context
These are reproductive-hormone endpoints, not pregnancy, live-birth, or sexual-function outcomes. Findings for kisspeptin-10 should not be conflated with trials of kisspeptin-54.

Source: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

29 registered studies name Kisspeptin-10 as an intervention; 5 are recruiting or under way, 0 have not started recruiting yet, 19 completed and 5 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism
NCT04648969 · Stephanie B. Seminara, MD
CompletedPhase 22019-05-0318
Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea
NCT07224438 · Stephanie B. Seminara, MD
RecruitingPhase 22025-12-0920
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
NCT07224490 · Stephanie B. Seminara, MD
RecruitingPhase 12026-03-1040
Kisspeptin Administration Subcutaneously to Patients With IHH
NCT05896293 · Stephanie B. Seminara, MD
RecruitingPhase 22023-02-0336
Functional Proteins in Polycystic Ovary Syndrome
NCT06793098 · Jagiellonian University
Recruiting2025-01-20100
Recall by Genotype: Neuropeptide Stimulation
NCT05901467 · Stephanie B. Seminara, MD
TerminatedPhase 12023-10-2016
Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test
NCT04958109 · Massachusetts General Hospital
CompletedPhase 12021-10-2816
Dampening the Reproductive Axis With Continuous Kisspeptin
NCT05971849 · Stephanie B. Seminara, MD
CompletedPhase 12023-10-068

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 29 listed studies.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Investigating the detection of the novel doping‐relevant peptide kisspeptin‐10 in urine using liquid chromatography high‐resolution mass spectrometry. ↗
Biomedical chromatography : BMC · 2024 Sep · English Abstract, Journal Article

Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src. ↗
Nature communications · 2024 Feb 12 · Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗

Author Correction: Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src. ↗
Nature communications · 2024 Dec 19 · Published Erratum
Read available full text ↗

Kisspeptin-10 increases collagen content in the myocardium by focal adhesion kinase activity. ↗
Scientific reports · 2023 Nov 15 · Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗

Repeat this PubMed search ↗

Related records in our PubMed snapshot

Kisspeptin-10/basal LH ratio improves differentiation of central precocious puberty and premature thelarche. ↗
Clinica chimica acta; international journal of clinical chemistry · Issue date 2027 Jan 1 · Not appraised

The kisspeptin analog C6 elicits greater tachyphylaxis and transcriptional activation than kisspeptin-10 and -54. ↗
Molecular and cellular endocrinology · Issue date 2026 Oct · Not appraised

Kisspeptin-10 Alleviates Obesity-induced Testicular Oxidative Stress and Mitochondrial Dysfunction via Modulation of Mitophagy and Autophagy Signaling. ↗
Reproductive sciences (Thousand Oaks, Calif.) · Issue date 2026 Sep 28 · Not appraised

Search additional PubMed records ↗

Risks & interactions

Kisspeptin-10 is an unapproved reproductive-hormone peptide. Only short studies in small groups of healthy men exist, and FDA lists it as a possible significant safety risk in compounding.

Human safety data: Very limited

Human studies are small and short, measuring hormone responses over hours to under two weeks. They do not establish reproductive, pregnancy or long-term endocrine safety, and FDA has only limited safety information.

Unassessed: little human safety data

It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Serious risks

  • FDA: possible immune reactions (immunogenicity) and impurity problems; too little data to know whether it causes harm

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Bulk drug substances that may present significant safety risks (category 2) ↗ · Kisspeptin-10 stimulates LH in men (2011) ↗ · Chronic kisspeptin-10 in healthy men (2026) ↗

Safety evidence & remaining uncertainty

FDA describes limited safety information. Brief exposure in a small group cannot establish reproductive, pregnancy, or long-term endocrine safety.

Source: FDA · Peptide compounding safety concerns ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Category 2 (FDA flagged significant safety risks)
Listed in 503A category 2 (significant safety risks) since September 29, 2023, citing immunogenicity risk, peptide-impurity complexity and limited safety data. FDA would consider action against compounders using it. source
World Anti-Doping Agency (2026)
Prohibited, named on the list · S2.2.1 Testosterone-stimulating peptides in males
Named ("kisspeptin and its agonist analogues"); prohibited in males. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & status

These physiology findings help explain the reproductive axis. They do not establish successful fertility treatment or sexual-function improvement from a commercial preparation.

Source: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Seller lab-report checks and prices are available to members. Sign up free

Mechanism & research rationale

Kisspeptin signaling stimulates GnRH-related pathways and downstream gonadotropin release. The selected human study examined LH pulses and testosterone.

Source: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. ↗

Molecular structure

Kisspeptin-10: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 25240297 ↗

Questions worth asking

  • What specific product, route, and research population does the claim refer to?
  • Does the source measure an outcome in people, or only a laboratory marker?
  • A short-term hormone response is different from a demonstrated fertility or sexual-function outcome.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Are kisspeptin-10 and kisspeptin-54 interchangeable study names?

No. They are different peptide lengths, and the exact intervention should be checked.

Source: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. ↗

Does a higher LH value demonstrate fertility improvement?

No. Clinical fertility outcomes such as pregnancy or live birth must be measured separately.

Source: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Kisspeptin-10

Download illustration ↓Source record ↗
Kisspeptin-10 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.